Efficacy of golimumab in Belgian patients with active rheumatoid arthritis despite treatment with non-biologic disease-modifying anti-rheumatic drugs: sub-analysis of the GO-MORE study

References

• Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–637 . Epub 2010 Mar 11.10.1136/ard.2009.123919
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509 . Epub 2013 Oct 29.10.1136/annrheumdis-2013-204573
   PubMed Web of Science ®Google Scholar
• Papagoras C, Voulgari PV, Drosos AA. Golimumab, the newest TNF-alpha blocker, comes of age. Clin Exp Rheumatol. 2015;33(4):570–7 . Epub 2015 Jan 21.
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, van der Heijde D, Keystone EC, Genovese MC, Conaghan PG, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: Results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011;63(5):1200–10 . Epub 2011 Feb 10.10.1002/art.30263
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Bingham CO 3rd, Mendelsohn AM, Kim L, Mack M, Lu J, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis. 2013;72(3):381–9 . Epub 2012 Jun 5.10.1136/annrheumdis-2012-201411
   PubMed Web of Science ®Google Scholar
• Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet. 2009;374(9685):210–21 . Epub 2009 Jun 30.10.1016/S0140-6736(09)60506-7
   PubMed Web of Science ®Google Scholar
• Alonso A, González CM, Ballina J, García Vivar ML, Gómez-Reino JJ, Marenco JL, et al. Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España. Reumatol Clin. 2015;11(3):144–50 . Epub 2014 Jul 16.10.1016/j.reuma.2014.05.002
   PubMed Web of Science ®Google Scholar
• Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, et al. Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study. Ann Rheum Dis. 2014;73(8):1477–86 . Epub 2013 Jun 7.10.1136/annrheumdis-2013-203229
   PubMed Web of Science ®Google Scholar
• Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North America. 2009;35(4):745–57, vii–viii. Epub 2009 Dec 8.
   PubMed Web of Science ®Google Scholar
• Anderson J, Caplan L, Yazdany J, Robbins ML, Neogi T, Michaud K, et al. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res. 2012;64(5):640–7 . Epub 2012 Apr 5.10.1002/acr.21649
   PubMed Web of Science ®Google Scholar
• Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatol (Oxford). 2003;42(2):244–57 . Epub 2003 Feb 22.10.1093/rheumatology/keg072
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis Rheum. 1980;23(2):137–45 . Epub 1980 Feb 1.10.1002/(ISSN)1529-0131
   PubMed Web of Science ®Google Scholar
• Putrik P, Ramiro S, Keszei AP, Hmamouchi I, Dougados M, Uhlig T, et al. Lower education and living in countries with lower wealth are associated with higher disease activity in rheumatoid arthritis: results from the multinational COMORA study. Ann Rheum Dis. 2016;75(3):540–6 . Epub 2015 Jan 30.10.1136/annrheumdis-2014-206737
   PubMed Web of Science ®Google Scholar
• Massardo L, Pons-Estel BA, Wojdyla D, Cardiel MH, Galarza-Maldonado CM, Sacnun MP, et al. Early rheumatoid arthritis in Latin America: low socioeconomic status related to high disease activity at baseline. Arthritis care & research. 2012;64(8):1135–43 . Epub 2012 Apr 17.
   Web of Science ®Google Scholar
• Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis. 2009;68(11):1666–72 . Epub 2009 Aug 1.10.1136/ard.2009.109983
   PubMed Web of Science ®Google Scholar
• Dasgupta B, Combe B, Louw I, Wollenhaupt J, Zerbini CA, Beaulieu A, et al. Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes. Arthritis Care Res. 2014;66(12):1799–807. Epub 2014 May 20.
   PubMed Web of Science ®Google Scholar